Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: B663; LAM320; Lamprene

Latest Information Update: 11 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University College Dublin
  • Developer Alliance Pharma plc; Novartis; University College Dublin; University of Pretoria
  • Class Antibacterials; Antileprotics; Phenazines
  • Mechanism of Action Adenosine triphosphatase inhibitors; DNA inhibitors; P-glycoprotein inhibitors; Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leprosy
  • Phase II/III Tuberculosis
  • Discontinued Acinetobacter infections; Liver cancer

Most Recent Events

  • 03 Apr 2017 Novartis intends to submit NDA to the US FDA for Tuberculosis in 2018
  • 11 Feb 2016 Phase-II/III clinical trials in Tuberculosis in Lithuania (PO) (EudraCT2015-004440-19)
  • 01 Apr 2003 No development reported - Phase-II for Liver cancer in South Africa (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top